KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Shares Issued (2016 - 2025)

BeOne Medicines (ONC) has disclosed Shares Issued for 10 consecutive years, with $19.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 118.79% to $19.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $196.3 million, a 332.59% increase, with the full-year FY2025 number at $196.3 million, up 332.59% from a year prior.
  • Shares Issued was $19.2 million for Q4 2025 at BeOne Medicines, down from $80.5 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $80.5 million in Q3 2025 to a low of $50000.0 in Q3 2021.
  • A 5-year average of $21.1 million and a median of $15.5 million in 2024 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: crashed 99.9% in 2021, then skyrocketed 33310.0% in 2022.
  • BeOne Medicines' Shares Issued stood at $42.8 million in 2021, then crashed by 73.61% to $11.3 million in 2022, then plummeted by 70.23% to $3.4 million in 2023, then skyrocketed by 161.76% to $8.8 million in 2024, then soared by 118.79% to $19.2 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Shares Issued are $19.2 million (Q4 2025), $80.5 million (Q3 2025), and $33.1 million (Q2 2025).